One Day Advisor

Updated October 30, 2026 Smart rings, AI-powered wearables and health apps are transforming consumer healthcare into a continuous-data business. Instead of relying on occasional doctor visits or annual health checks, consumers can monitor sleep, heart rate, activity, recovery, stress and selected physiological signals throughout the day. For technology companies and investors, the more important development is not simply the sale of another wearable device. It is the opportunity to turn a physical product into an ongoing relationship through recurring subscriptions, personalized analytics, AI coaching, health services and business-to-business partnerships. However, a commercially successful wearable is not necessarily a clinically effective one. Accurate measurement of a physiological signal does not automatically translate into a reliable disease prediction, a better health outcome or a reduction in healthcare costs. This independent analysis examines the business models, r...

Last updated: October 30, 2026 Pharmaceutical companies face a recurring challenge: blockbuster medicines eventually lose patent protection or other forms of market exclusivity, allowing generic drugs or biosimilars to compete. The resulting price and market-share declines can put billions of dollars in annual sales at risk. For investors, however, the important question is not simply when does a drug go off patent? It is whether the company has developed, acquired or launched enough new products to replace the revenue that may disappear. This Pharma Patent-Cliff and Pipeline Replacement Tracker connects four investment questions: Which major drugs face generic or biosimilar competition, and when? How much annual product revenue is exposed? Which approved medicines and pipeline candidates could help replace those sales? Is the company demonstrating replacement through actual revenue growth, or relying primarily on future clinical and regulatory milestones? The an...